Lung Cancer
PET scanning improves the selection of patients for combined modality treatment
Published in Cancer Weekly, April 22nd, 2003
According to recent research from the Netherlands, "Combined modality treatment (CMT) for patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) is at present studied extensively.
"To select patients with truly stage IIIA-N2 disease, however, proves to be difficult with current diagnostic tests. Distant metastases may become clinically overt during induction chemotherapy (IC) or shortly after, revealing the inaccuracies of current staging algorithms," wrote C.J. Hoekstra and colleagues, Vrije University, Amsterdam Medical Center.
"A...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-04-22)
More Articles from Cancer Weekly
- Cancer Metastasis
Interleukin-1 is a prerequisite for tumor invasion and angiogenesis - Gene Detection
Dual "molecular beacons" might eventually lead to very early cancer diagnosis - Antiangiogenesis
A new hypoxia-dependent agent inhibits tumor-specific neovascularization - Bladder Cancer
Hexvix cystoscopy improves treatment of patients - new phase III results - Body Mass Index
Height, but not weight or BMI, associated increases risk of testicular cancer - Liver Cancer
Researchers probe promising treatment - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
